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Abstract
Purpose Poor left ventricular (LV) function may affect the physiological intraventricular blood flow and physiological vortex 
formation. The aim of this study was to investigate the pattern of intraventricular blood flow dynamics in patients with LV 
assist devices (LVADs) using echocardiographic particle image velocimetry.
Materials and methods This prospective study included 17 patients (mean age 57 ± 11 years, 82% male) who had received an 
LVAD (HeartMate 3, Abbott Laboratories, Chicago, Illinois, USA) because of end-stage heart failure and poor LV function. 
Eleven (64%) patients had ischemic cardiomyopathy, and six patients (36%) had nonischemic cardiomyopathy. All patients 
underwent echocardiography, including intravenous administration of an ultrasound-enhancing agent (SonoVue, Bracco, 
Milan, Italy). Echocardiographic particle image velocimetry was used to quantify LV blood flow dynamics, including vortex 
formation (Hyperflow software, Tomtec imaging systems Gmbh, Unterschleissheim, Germany).
Results Contrast-enhanced ultrasound was well tolerated in all patients and was performed without adverse reactions or 
side effects. The LVAD function parameters did not change during or after the ultrasound examination. The LVAD flow 
was on average 4.3 ± 0.3 L/min, and the speed was 5247 ± 109 rotations/min. The quantification of LV intraventricular flow 
demonstrated substantial impairment of vortex parameters. The energy dissipation, vorticity, and kinetic energy fluctuation 
indices were severely impaired.
Conclusions Echo particle velocimetry is safe and feasible for the quantitative assessment of intraventricular flow in patients 
with an LVAD. The intraventricular LV flow and vortex parameters are severely impaired in these patients.
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Introduction
Patients with end-stage heart failure and poor left ven-
tricular (LV) function due to ischemic or nonischemic car-
diomyopathy may benefit from therapy with an LV assist 
device (LVAD). These devices may significantly improve 
patients’ quality of life, alleviate symptoms, and prolong 
life, but there are concerns about complications, including 
thrombosis, stroke, and device durability [1–3]. Some of 
these LVAD-related complications are possibly a result of 
impaired physiological blood flow dynamics.
Echocardiographic particle image velocimetry combined 
with an ultrasound-enhancing agent is a novel method for 
quantitatively assessing intraventricular blood flow dynam-
ics [4]. The ultrasound-enhancing agent consists of micro-
bubbles, which have a size comparable to that of erythro-
cytes and which serve as a tracer of intraventricular blood 
flow [5, 6]. Recently, this method has successfully been 
explored in experimental and clinical research settings 
[7–11]. In a normal heart, the size and shape of the LV, 
together with the orientation of the valves, favor vortex for-
mation and spontaneous redirection of the blood flow from 
the LV inflow to the LV outflow tract [4]. The physiologi-
cal vortex formation is supposed to be an energy-efficient 
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arrangement to avoid excessive wall stress and optimize LV 
pump performance. Presumably, poor LV function, in addi-
tion to pathological alterations in heart volume and shape 
in patients with ischemic or nonischemic cardiomyopathy, 
affects intraventricular blood flow dynamics and vortex for-
mation. Moreover, in patients with advanced heart failure 
due to poor LV function who receive LVAD therapy, the 
inflow cannula located near the LV apex and the continuous 
suction of the device may affect blood flow dynamics and 
vortex formation.
The ultimate goal of echo particle velocimetry in patients 
with an LVAD is to obtain an improved understanding of LV 
blood flow dynamics, to optimize treatment, and to reduce 
the number of blood-flow-related complications. The aim 
of this study was to investigate the pattern of intraventricu-
lar blood flow dynamics in patients with an LVAD using 
echocardiographic particle image velocimetry. The degree of 
blood flow disturbance was quantified by energy dissipation, 
vorticity, and kinetic energy fluctuation indices.
Methods
Consecutive ambulatory patients who had received an 
LVAD (HeartMate 3, Abbott Laboratories, Chicago, Illinois, 
USA) because of end-stage heart failure due to ischemic or 
nonischemic cardiomyopathy and poor LV function were 
asked to participate in this prospective study. The study pro-
tocol was approved by the Medical Ethics Committee of 
the Erasmus Medical Center, Rotterdam, The Netherlands. 
All patients provided a signed informed consent form. All 
patients underwent transthoracic echocardiography using an 
ultrasound-enhancing agent. Exclusion criteria were con-
traindications for the use of an ultrasound-enhancing agent, 
such as unstable angina, acute cardiac failure, acute endo-
carditis, and known allergies for ultrasound contrast agents.
Transthoracic echocardiography was performed with a 
Philips Epiq 7C ultrasound system (Philips Medical Sys-
tems, Bothell, USA), using an X5-1 transducer. A stand-
ardized image acquisition protocol based on the American 
Society of Echocardiography guidelines was used [12]. Par-
asternal long-axis and short-axis views, as well as apical 
four-, two-, and three-chamber views, were obtained using 
B-mode ultrasound and color Doppler imaging.
Contrast-enhanced echocardiography was performed 
using the contrast mode of the ultrasound system, which 
employs amplitude modulation techniques and a mechanical 
index of 0.1–0.5 to optimize the images. The sector width 
and depth were optimized to obtain complete LV views and 
to maximize the frame rate. The ultrasound-enhancing agent 
(SonoVue™, sulfur hexafluoride microbubble suspension, 
Bracco S.p.A., Milan, Italy) was administered intravenously 
in boluses of 0.5 mL. Image acquisition was performed 
during the dilution phase, which follows the peak concen-
tration of the ultrasound-enhancing agent, when the LV was 
homogeneously filled for an optimal visualization of blood 
flow, while avoiding both saturation and black areas [4]. The 
bolus administration was repeated when necessary up to a 
total dose of 5.0 mL. During and after administration of 
the ultrasound-enhancing agent, patients were observed for 
potential side effects or complications, and LVAD function 
parameters were monitored. For both standard and contrast 
echocardiographies, cine clips were digitally stored and 
reviewed offline. The standard and contrast echocardio-
graphic studies were reviewed offline by two observers una-
ware of the clinical data. Quantitative analysis of LV blood 
flow dynamics was performed offline using Hyperflow soft-
ware (Tomtec imaging systems Gmbh, Unterschleissheim, 
Germany). This software package was previously validated 
and has good accuracy for the assessment of intraventricu-
lar flow and flow direction [9, 10]. The software does not 
depend on anthropometric parameters. Electrocardiographic 
tracing was used to confirm the systolic and diastolic phases. 
The vortex calculations were performed in the apical three-
chamber view. Vortex parameters were computed from the 
steady-streaming vortex, including the vortex area normal-
ized to the LV area, the vortex intensity (the integral of the 
vorticity inside the vortex) normalized to the total vorticity, 
the vortex depth (the distance from the vortex center to the 
vortex base), and the vortex length along the base–apex 
direction, both normalized to the LV length.
Statistical analyses were performed using SPSS for 
Windows (version 17.0, SPSS, Chicago, USA) and Excel 
(Excel 2003, Microsoft, Redmont, USA). Continuous vari-
ables are reported as mean ± standard deviation. Categori-
cal variables are expressed as percentages. The Chi-square 
test was used to evaluate differences between proportions. 
A p value < 0.05 was considered to indicate a statistically 
significant difference.
Results
The baseline characteristics of the study population (mean 
age 57 ± 11 years, 82% male) are presented in Table 1. 
Eleven (65%) patients had received an LVAD because of 
ischemic cardiomyopathy, and six patients (35%) had noni-
schemic cardiomyopathy.
Contrast-enhanced ultrasound was well tolerated in all 
patients and was performed without adverse reactions or side 
effects. The LVAD function parameters did not change dur-
ing or after the ultrasound examination. The LVAD flow was 
on average 4.3 ± 0.3 L/min, and the speed was 5247 ± 109 
rotations/min. There were no signs that the LVAD caused 
substantial destruction of the ultrasound contrast agent; a 
regular dose of contrast agent could be used in all cases.
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The results of the LV intraventricular flow quantification 
are presented in Table 2. Overall, substantial impairment of 
vortex parameters was observed in comparison with previ-
ously published normal values [9, 10]. The energy dissipa-
tion, vorticity, and kinetic energy fluctuation indices were 
severely impaired. Figure 1 provides an example of LV intra-
ventricular flow analysis in a patient with an LVAD.
Discussion
This study demonstrates that LV intraventricular flow quanti-
fication with contrast-enhanced echocardiography in patients 
with an LVAD is safe and feasible. The main findings are 
that LV flow and vortex parameters are severely impaired 
in these patients. The observed intraventricular flow abnor-
malities are probably the result of pathophysiologic changes 
related to poor LV function and alterations in LV size and 
shape. Moreover, the LVAD inflow cannula is positioned 
near the LV apex, which affects the intraventricular flow 
and vortex formation. Previous observations have suggested 
that one of the benefits of an LV vortex is that it can mini-
mize kinetic energy dissipation and reduce the total energy 
that is needed for LV ejection, resulting in more efficient 
energy use during the cardiac cycle [4, 9, 10]. Impairment 
of the vortex area or vortex intensity, which was observed in 
patients with poor LV function, may affect intraventricular 
flow efficiency, eventually leading to further deterioration in 
LV function and adverse LV remodeling.
In this study, the quantification of LV flow was performed 
by offline analysis of contrast-enhanced echocardiography 
using a previously validated nonvendor-specific software 
package called Hyperflow (Tomtec imaging systems Gmbh, 
Unterschleissheim, Germany). This echo particle image 
velocimetry software has good accuracy for the direction 
of flow and the quantification of low flow velocities, such 
as intraventricular flow [9, 10]. A limitation of this software 
is the estimation of higher flow velocities, such as the flow 
rate during peak velocity and the flow rate near the heart 
valves, which are underestimated because of the relatively 
low frame rate during image acquisition [9, 10]. However, 
this limitation is probably less relevant in patients with an 
LVAD because intraventricular flows are expected to be in 
the low-velocity range.
Agati et al. [9] studied intraventricular blood flow using 
quantitative echo particle image velocimetry in 34 con-
secutive patients with an ST elevation myocardial infarc-
tion (STEMI) and 30 healthy control subjects. The highest 
energy dissipation was observed in STEMI patients with 
a preserved global LV function, suggesting a fluid–tissue 
dynamical balance as a compensatory mechanism for main-
taining adequate LV function. In patients with STEMI and 
a significantly reduced LV function, energy dissipation was 
reduced as a consequence of a low flow kinetic energy.
Cimino et al. [10] studied 32 patients with dilated cardio-
myopathy who underwent cardiac resynchronization therapy 
(CRT). All patients underwent echo particle velocimetry 
6 months after CRT during active CRT and during a tem-
porarily discontinued CRT state. Energy dissipation, vortex 
area, and vorticity fluctuation were significantly higher in 
nonresponder patients during a temporarily discontinued 
CRT. During active CRT, these flow parameters further 
deteriorated in nonresponder patients.
The patient population in these previous studies [9, 10] 
differs from the current population of patients in that all our 
patients had advanced heart failure and poor LV function 
for which they had received an LVAD; these factors cer-
tainly have an influence on LV intraventricular flow dynam-
ics. The methodology in the previous studies was similar. 
Both used contrast-enhanced echocardiography with the 
Table 1  Clinical characteristics of the study population
Data are presented as numbers of patients (percentages) or as 
mean ± standard deviation
BMI Body mass index, NYHA New York Heart Association
Characteristic Data
Age (years) 57 ± 11
Men 14 (82)
Height (cm) 179 ± 8
Weight (kg) 80 ± 12
BMI (kg/m2) 25 ± 4
Heart rate (beats/min)
Systolic blood pressure (mmHg)






NYHA class 4 12 (71)
Ischemic cardiomyopathy 11 (65)
Nonischemic cardiomyopathy 6 (35)
Previous paroxysmal atrial fibrillation 7 (41)
Previous ventricular tachycardia 11 (65)
Percutaneous coronary intervention 7 (41)
Coronary bypass surgery 4 (24)
Table 2  Intraventricular flow quantification (n = 17)
Data are presented as mean ± standard deviation
Measured value
Vortex area 0.30 ± 0.09
Vortex length 0.65 ± 0.17
Vortex depth 0.45 ± 0.08
Vortex intensity − 0.36 ± 0.12
Energy dissipation index 0.96 ± 0.57
Vortex fluctuation index 0.75 ± 0.15
Kinetic energy fluctuation index 1.34 ± 0.46
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same ultrasound-enhancing agent (SonoVue, Bracco, Milan, 
Italy), and the same software package (Hyperflow, Tomtec 
imaging systems Gmbh, Unterschleissheim, Germany) was 
used for LV flow quantification as in the current study. The 
findings of the current study are in line with those of the 
previous two studies and show significant impairment of 
LV flow and vortex parameters in patients with poor LV 
function.
In patients with advanced heart failure due to poor LV 
function, LVAD therapy may significantly improve symp-
toms and prolong life expectancy [1–3]. However, several 
complications of LVAD therapy have been recognized, 
including LV thrombus formation, which may result in 
thromboembolic events such as stroke [1–3]. The present 
study demonstrated that a subgroup of patients with LVAD 
(four out of 17, 24%) had no LV output, and echo particle 
image velocimetry showed that in this subgroup, vortex area 
and vortex intensity were most severely affected. Further 
studies are needed to assess whether this subgroup has an 
increased risk of thromboembolic complications during 
follow-up. Subsequently, strategies such as an intensified 
anticoagulation treatment or a modification of LVAD set-
tings can be evaluated in an attempt to reduce the risk of 
thrombosis.
This study showed, for the first time, that echo particle 
velocimetry allows the visualization of LV flow in patients 
with an LVAD. The main observation is that the physiologi-
cal intraventricular flow and vortex formation are severely 
affected in these patients. In future studies, this method can 
be used as a tool to optimize intraventricular flow, possi-
bly minimizing energy consumption during systole. Several 
modifiable factors may influence the intraventricular flow in 
patients with an LVAD, such as the exact implantation site of 
the LV cannula, the LVAD settings, and the LV filling state. 
Furthermore, additional factors, such as concomitant valve 
disease, atrioventricular and intraventricular conduction 
abnormalities, fluid balance, and systemic blood pressure, 
can be amendable factors for optimizing the intraventricular 
flow in these patients.
This study demonstrates that echo particle velocimetry is 
feasible and provides meaningful results, but it has several 
limitations. First, the study population was small because 
this was a prospective pilot study. Second, the presence of 
the LVAD hindered the acquisition of standard echocardio-
graphic views in some patients because the inflow cannula 
was located near the LV apex. This limitation was overcome 
by a slightly modified transducer position, which may have 
resulted in marginally off-axis apical views. Third, the soft-
ware package has good accuracy for the assessment of flow 
direction and the quantification of low flow velocities, but 
it underestimates high flow velocities [4, 9, 10]. Finally, no 
extensive safety data on the use of ultrasound-enhancing 
agents in patients with an LVAD are available. Recent small 
studies indicate that the use of ultrasound-enhancing agents 
in these patients is safe and results in improved image qual-
ity and a better delineation of endocardial borders [13, 14]. 
Fig. 1  Example of LV intraventricular flow analysis using echo par-
ticle velocimetry in a patient with an LVAD (three-chamber apical 
view). a Demonstrates the intraventricular flow during diastole, with 
blood entering the LV, showing the LV blood flow toward the apex, 
where the LVAD inflow cannula is positioned. During systole (b), the 
intraventricular flow is directed toward the left ventricular outflow 
tract (LVOT). A clockwise intraventricular vortex is demonstrated in 
blue. c Demonstrates the position of the left ventricle (LV), left ven-
tricular apex, mitral valve (MV), and aorta (Ao)
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Contrast-enhanced ultrasound also has the potential to reveal 
rare vascular complications [15].
Conclusion
Echo particle velocimetry is safe and feasible for the quan-
titative assessment of intraventricular flow in patients who 
have received an LVAD because of advanced heart failure 
and poor LV function. The intraventricular LV flow and vor-
tex parameters are severely impaired in these patients.
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